Skip to Main Content

Paper Details

Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
J Immunother Cancer
18
2019
APS-2, Autoimmune polyendocrine syndrome type II, BRAF, BRAF wild-type melanoma, C-peptide, DR4, DR4 serotype, HLA, HLA Class II, HLA class II, HLA-DR4 serotypes, HLA-DRB1*, HLA-DRB1*04, PD1, T1DM, anti-, anti-PD1, anti-programmed cell death protein 1, autoimmune diabetes, autoimmune hypoadrenalism, autoimmune polyendocrine syndrome type II, diabetes, human, human leukocyte antigen (HLA) DR3, hypoadrenalism, hypothyroidism, islet cells, melanoma, patients, pembrolizumab, poly-endocrinopathy, programmed cell death protein 1, thyroid dysfunction, type 1 diabetes, woman
Author NameAffiliation
Damien Kee
Damien KeeUniversity of Melbourne
Jonathan Cebon
Jonathan CebonOlivia Newton-John Cancer Research Institute, La Trobe University
  • 1 - 4

Datasets

Release 1.2